A 2026 study of young breast cancer survivors found that fewer than half of those on endocrine therapy had a recent bone density scan — the lowest adherence rate of any preventive measure tracked. Here's how survivorship programs can close that gap without adding staff.
Bone loss is one of the most predictable, best-documented late effects of cancer treatment — and one of the easiest to miss. Aromatase inhibitors, androgen deprivation therapy, chemotherapy-induced ovarian failure, and long-term corticosteroid use all accelerate bone density loss well beyond what's expected from normal aging, putting survivors at elevated risk for osteoporosis and fracture years after active treatment ends. Professional guidance on how to screen for and manage this risk has existed for years. What a newly published study makes clear is that guidance and practice have drifted apart, and survivorship programs are well positioned to close that gap.
A study published in the July 2026 issue of JCO Oncology Practice followed 660 women diagnosed with stage 0–III breast cancer at age 40 or younger, surveyed roughly seven years after diagnosis.[1] Among the 232 women in that cohort taking endocrine therapy, only 42% reported a bone density scan in the prior two years — the lowest adherence rate of any preventive measure the study tracked, trailing mammography (82%), Pap testing (76%), flu vaccination (68%), and cholesterol screening (56%). Bone health, in other words, isn't falling through the cracks because survivors are disengaged from preventive care in general. It's falling through a specific gap in how follow-up is structured.
Who Carries Elevated Fracture Risk After Cancer Treatment
The population at risk is larger and more varied than "women on aromatase inhibitors," though that group is the most visible example. ASCO's clinical practice guideline on managing osteoporosis in adult cancer survivors identifies several treatment exposures that accelerate bone loss well beyond typical age-related decline: aromatase inhibitor therapy in postmenopausal women, androgen deprivation therapy in men treated for prostate cancer, GnRH agonist–induced ovarian suppression, chemotherapy-induced premature ovarian failure, chronic glucocorticoid use above a modest dose threshold, and prior bone marrow transplantation.[2] Traditional risk factors — advanced age, smoking, excess alcohol use, prior fragility fracture, low body weight, and family history of hip fracture — compound risk further and should factor into how aggressively a given survivor is screened and managed.
That's a meaningful share of the survivorship population: essentially anyone treated with endocrine therapy for hormone-sensitive breast cancer, anyone on long-term ADT for prostate cancer, and a substantial subset of patients treated with cytotoxic chemotherapy or transplant regimens at almost any age. More than 3.9 million women in the United States are living with a history of breast cancer, and hormone-sensitive disease treated with extended endocrine therapy is common enough that bone health surveillance can't reasonably be treated as a niche concern reserved for a cardio-oncology-style subspecialty clinic.[3] It has to be a routine, structural part of survivorship follow-up.
What the Guidelines Actually Call For
The clinical guidance itself is not new or ambiguous. ASCO recommends baseline bone mineral density testing for survivors with one or more risk factors, followed by DEXA rescreening approximately every two years — more frequently if a patient's bone density is near a treatment threshold or their clinical picture changes, but generally not more than annually.[2] Pharmacologic treatment with a bone-modifying agent — oral or IV bisphosphonates, or subcutaneous denosumab — is indicated at a T-score of −2.5 or below at the hip or spine, or when FRAX-calculated 10-year fracture probability reaches 20% for major osteoporotic fracture or 3% for hip fracture. Because cancer-treatment-driven bone loss can progress faster than the typical age-related decline those thresholds were built around, the guideline explicitly notes that clinicians may reasonably consider treatment at a higher T-score for patients on aromatase inhibitors or ADT.
Alongside pharmacologic management, the guideline calls for calcium intake of 1,000–1,200 mg per day and vitamin D intake of at least 800–1,000 IU per day, with higher vitamin D doses considered for patients on bone-loss-inducing therapy, plus a baseline 25-OH vitamin D level before starting AI or ADT. It also recommends a combination of weight-bearing, resistance, balance, and flexibility exercise tailored to the individual, and active counseling on smoking cessation and alcohol moderation as modifiable risk factors.[2] None of this requires new technology or a novel clinical pathway. It requires a mechanism to make sure it actually happens on schedule, for the right patients, without depending on any one clinician remembering to order it.
Why the Screening Gap Persists
The JCO Oncology Practice study points directly at the operational reason bone health screening lags behind other preventive measures: fragmented follow-up. Ninety-two percent of survivors in the cohort reported having a primary care provider, but only 29% saw both a PCP and an oncology provider for cancer-related follow-up care; 57% saw an oncology provider only.[1] Bone density screening sits in an awkward zone of that handoff — it's a preventive service that primary care providers are accustomed to ordering for general osteoporosis risk in older patients, but the trigger for a cancer survivor is treatment-specific (an AI or ADT start date, a cumulative glucocorticoid exposure, a chemotherapy regimen associated with ovarian failure) and often invisible to a PCP who isn't tracking oncology treatment history in detail. Meanwhile, oncology teams that do have that treatment history are frequently past the point in the care relationship where routine preventive screening feels like their responsibility to initiate.
The result is a service that both sides of the care team could plausibly order, and that, absent a defined owner, often isn't ordered by either. That's a familiar pattern for survivorship program leaders: it's structurally similar to the gaps that have already prompted programs to build formal pathways for fertility counseling, secondary cancer surveillance, and cardiovascular risk (see our recent piece on building a cardio-oncology pathway). Bone health belongs in that same category of late effect that is well understood clinically but poorly operationalized without a structured pathway.
Building a Bone Health Pathway Without New Headcount
Closing this gap doesn't require a bone health specialty clinic, a new nurse navigator role, or a manual chart-review process layered onto an already-stretched survivorship team. What it requires is treating bone health surveillance the way a well-built survivorship care plan already treats other treatment-driven risks: as a data-triggered task rather than a discretionary judgment call.
In practice, that means capturing the specific treatment exposures that drive bone loss — aromatase inhibitor start date and expected duration, ADT initiation, ovarian suppression therapy, cumulative glucocorticoid exposure, transplant history — as structured fields in the survivorship record rather than free-text notes. From there, DEXA screening due-dates can be generated automatically on the two-year cadence ASCO recommends, flagged to whichever provider is actually managing the patient's follow-up at that point, whether that's oncology, primary care, or both. Baseline calcium and vitamin D counseling can be built into the same care plan patients already receive at treatment initiation, rather than left to whichever clinician happens to think of it. And because the underlying risk stratification is treatment-history-driven rather than manually assessed, it doesn't degrade as a survivor moves further from active treatment or transitions between providers — which is exactly the point in care where this study shows the gap widens.
This is the same logic that applies across late-effects surveillance generally: the clinical guidance is rarely the hard part. The hard part is making sure a treatment history captured at diagnosis reliably produces the right action years later, regardless of which clinician is in the room or how many providers have changed since. Programs that build that connectivity into their survivorship infrastructure once can apply it to bone health, cardiovascular risk, fertility, and secondary cancer surveillance alike — without adding a new workflow, a new spreadsheet, or new staff for every late effect that guidelines eventually catch up to.
If your survivorship program is looking to build structured, treatment-history-driven surveillance for bone health or other late effects without adding operational burden, we'd welcome a conversation about how a scalable, evidence-based survivorship platform can help.
Sources
Ssebyala SN, Zheng Y, Riley E, et al. "Health Care Utilization and Follow-Up Care in Young Adult Breast Cancer Survivors." JCO Oncology Practice. 2026;22(7):1286-1294. https://pubmed.ncbi.nlm.nih.gov/40991876/
Shapiro CL, Van Poznak C, Lacchetti C, et al. "Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline." Journal of Clinical Oncology. 2019;37(31):2916-2946. https://ascopubs.org/doi/10.1200/JCO.19.01696
National Cancer Institute, SEER Cancer Stat Facts: Female Breast Cancer. https://seer.cancer.gov/statfacts/html/breast.html